The DOI matches its Crossref record.
Survey research methods
Open accessAbstract
Introduction Mirikizumab (miri) is a humanized, IgG4 monoclonal antibody directed against the p19 subunit of IL-23, a key mediator in the pathogenesis of IBD. We assessed the induction efficacy and safety of miri with a Phase 3, multi-center, randomized, parallel-arm, double-blind, placebo (PBO)-controlled trial (LUCENT 1; NCT03518086) in patients with moderate-to-severe ulcerative colitis (UC) who had inadequate or loss of response, or intolerance to corticosteroids, immunosuppressants, biologic therapies, or tofacitinib. Methods Adult patients (N=1281) were randomized in a 3:1 ratio to receive blinded intravenous administration of 300mg miri or PBO every 4weeks for 12weeks. Randomization was stratified by biologic failure status, baseline (BL) corticosteroid use, BL disease activity as measured by modified Mayo score, and world region. The primary objective was to test the hypothesis that miri was superior to PBO in inducing clinical remission at Week12. Key secondary objectives were clinical response, endoscopic and symptomatic remission, clinical response in biologic-failed patients, histologic-endoscopic mucosal improvement, and improvement in bowel urgency at Week12. Results BL characteristics were balanced across the 2 treatment groups. A significantly greater proportion of patients treated with miri achieved clinical remission at Week12 (Miri: 24.2%; PBO: 13.3%; Δ=11.1 [99.875%CI: 3.2, 19.1]; p=0.00006). Miri-treated patients achieved all key secondary endpoints, including a significantly greater average reduction in bowel urgency severity compared to PBO (p<0.00001). The frequencies of treatment-emergent adverse events (AEs) in miri-treated patients were similar to PBO. There were numerically fewer serious AEs (Miri: 27 [2.8%], PBO: 17 [5.3%]) and discontinuations due to AEs (Miri: 15 [1.6%], PBO: 23 [7.2%]) in miri-treated patients compared to PBO. There were 2 colon malignancies in the miri arm (0.2%) and no deaths during the treatment period. Conclusions In this Phase 3 UC study, 300mg miri IV demonstrated statistically significant and clinically meaningful improvements vs PBO in all primary and key secondary endpoints across clinical, endoscopic, histologic, and symptomatic measures, with an acceptable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeted Sampling: Options for the Study of Hidden Populations
Watters, J. K., & Biernacki, P. (1989) · Social Problems · doi:10.1525/sp.1989.36.4.03a00070 · Cited by 1,516
Bekkers, R., & Wiepking, P. (2011) · Nonprofit and Voluntary Sector Quarterly · doi:10.1177/0899764010380927 · Cited by 1,503
How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?
Fewtrell, M. S., Kennedy, K., Singhal, A., Martin, R. M., Ness, A., Hadders-Algra, M., Koletzko, B., & Lucas, A. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.127316 · Cited by 601
Byrne, B. M., & van de Vijver, F. J. R. (2010) · International Journal of Testing · doi:10.1080/15305051003637306 · Cited by 575
Gulati, R., & Westphal, J. D. (1999) · Administrative Science Quarterly · doi:10.2307/2666959 · Cited by 569
Metadata
- Authors
- THOMAS, H. F.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-09-01
- Volume
- 75
- Issue
- 887
- Pages
- 575-575
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2078618893
- Cited by
- 279
- References
- 0
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survey research methods. https://app.cochat.ai/papers/10.1136/pgmj.75.887.575b
- The paper
- THOMAS, H. F. (1999). Survey research methods. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.75.887.575b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.